Target enrichment using parallel nanoliter quantitative PCR amplification
Bram De Wilde, Steve Lefever, Wes Dong et al. · BMC Genomics · 2014
BACKGROUND: Next generation targeted resequencing is replacing Sanger sequencing at high pace in routine genetic diagnosis. The need for well validated, high quality enrichment platforms to complement the bench-top next generation sequencing devices is high. RESULTS: We used the WaferGen Smartchip platform to perform highly parallelized PCR based target enrichment for a set of known cancer genes in a well characterized set of cancer cell lines from the NCI60 panel. Optimization of PCR assay design and cycling conditions resulted in a high enrichment efficiency. We provide proof of a high mutation rediscovery rate and have included technical replicates to enable SNP calling validation demonstrating the high reproducibility of our enrichment platform. CONCLUSIONS: Here we present our custom developed quantitative PCR based target enrichment platform. Using highly parallel nanoliter singleplex PCR reactions makes this a flexible and efficient platform. The high mutation validation rate shows this platform's promise as a targeted resequencing method for multi-gene routine sequencing diagnostics.
Cited by 19 works. doi:10.1186/1471-2164-15-184 Open-access PDF
Authors
References
- Fast and accurate short read alignment with Burrows–Wheeler transform
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
- Integrated genomic analyses of ovarian carcinoma
- The Consensus Coding Sequences of Human Breast and Colorectal Cancers
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
- A comprehensive catalogue of somatic mutations from a human cancer genome
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
- A small-cell lung cancer genome with complex signatures of tobacco exposure
- The impact of next-generation sequencing technology on genetics
- Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma